{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:27:30Z","timestamp":1791120450089,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1756-8722-7-33","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T19:01:41Z","timestamp":1397502101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies"],"prefix":"10.1186","volume":"7","author":[{"given":"Caroline S","family":"Breton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimable","family":"Nahimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Macoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bertschinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A","family":"Duchosal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,14]]},"reference":[{"key":"385_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00277-003-0752-8","volume":"83","author":"N Gokbuget","year":"2004","unstructured":"Gokbuget N, Hoelzer D: Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol. 2004, 83: 201-205. 10.1007\/s00277-003-0752-8.","journal-title":"Ann Hematol"},{"key":"385_CR2","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","volume":"29","author":"R Bassan","year":"2011","unstructured":"Bassan R, Hoelzer D: Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011, 29: 532-543. 10.1200\/JCO.2010.30.1382.","journal-title":"J Clin Oncol"},{"key":"385_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00003495-200767030-00002","volume":"67","author":"MA Fanale","year":"2007","unstructured":"Fanale MA, Younes A: Monoclonal antibodies in the treatment of non-Hodgkin\u2019s lymphoma. Drugs. 2007, 67: 333-350. 10.2165\/00003495-200767030-00002.","journal-title":"Drugs"},{"key":"385_CR4","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1056\/NEJMct1114348","volume":"366","author":"DG Maloney","year":"2012","unstructured":"Maloney DG: Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012, 366: 2008-2016. 10.1056\/NEJMct1114348.","journal-title":"N Engl J Med"},{"key":"385_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/asheducation-2011.1.243","volume":"2011","author":"D Hoelzer","year":"2011","unstructured":"Hoelzer D: Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2011, 2011: 243-249. 10.1182\/asheducation-2011.1.243.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"385_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00281-006-0057-9","volume":"28","author":"TF Tedder","year":"2006","unstructured":"Tedder TF, Baras A, Xiu Y: Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol. 2006, 28: 351-364. 10.1007\/s00281-006-0057-9.","journal-title":"Springer Semin Immunopathol"},{"key":"385_CR7","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3324\/haematol.2011.047159","volume":"96","author":"P Boross","year":"2011","unstructured":"Boross P, Jansen JH, De Haij S, Beurskens FJ, van der Poel CE, Bevaart L, Nederend M, Golay J, van de Winkel JG, Parren PW, Leusen JH: The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 2011, 96: 1822-1830. 10.3324\/haematol.2011.047159.","journal-title":"Haematologica"},{"key":"385_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1746-1596-6-33","volume":"6","author":"VK Prevodnik","year":"2011","unstructured":"Prevodnik VK, Lavrencak J, Horvat M, Novakovic BJ: The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011, 6: 33-10.1186\/1746-1596-6-33.","journal-title":"Diagn Pathol"},{"key":"385_CR9","first-page":"611","volume":"5","author":"TA Davis","year":"1999","unstructured":"Davis TA, Czerwinski DK, Levy R: Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999, 5: 611-615.","journal-title":"Clin Cancer Res"},{"key":"385_CR10","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.4049\/jimmunol.177.10.7435","volume":"177","author":"ME Williams","year":"2006","unstructured":"Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Eggleton JC, Taylor RP: Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006, 177: 7435-7443.","journal-title":"J Immunol"},{"key":"385_CR11","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2009-06-229112","volume":"115","author":"C Henry","year":"2010","unstructured":"Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Remy-Martin JP, Callanan M, Traverse-Glehen A, GrandClement C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C: Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood. 2010, 115: 2420-2429. 10.1182\/blood-2009-06-229112.","journal-title":"Blood"},{"key":"385_CR12","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","volume":"172","author":"AD Kennedy","year":"2004","unstructured":"Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP: Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004, 172: 3280-3288.","journal-title":"J Immunol"},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaci.2007.11.030","volume":"121","author":"MC Levesque","year":"2008","unstructured":"Levesque MC, St Clair EW: B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol. 2008, 121: 13-21. 10.1016\/j.jaci.2007.11.030. quiz 22-13","journal-title":"J Allergy Clin Immunol"},{"key":"385_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/10428199509059636","volume":"18","author":"RH Scheuermann","year":"1995","unstructured":"Scheuermann RH, Racila E: CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995, 18: 385-397. 10.3109\/10428199509059636.","journal-title":"Leuk Lymphoma"},{"key":"385_CR15","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood.V63.6.1424.1424","volume":"63","author":"KC Anderson","year":"1984","unstructured":"Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984, 63: 1424-1433.","journal-title":"Blood"},{"key":"385_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2141.2011.08857.x","volume":"155","author":"E Ward","year":"2011","unstructured":"Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall\u2019Acqua W, Tedder T, Kiener P, Coyle AJ, Wu H, Jallal B, Herbst R: A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol. 2011, 155: 426-437. 10.1111\/j.1365-2141.2011.08857.x.","journal-title":"Br J Haematol"},{"key":"385_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00262-009-0746-z","volume":"59","author":"PM Cardarelli","year":"2010","unstructured":"Cardarelli PM, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis MC, Pan C, Preston B, Passmore D, Liu J, Kuhne MR, Witte A, Blanset D, King DJ: A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010, 59: 257-265. 10.1007\/s00262-009-0746-z.","journal-title":"Cancer Immunol Immunother"},{"key":"385_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.leukres.2007.07.002","volume":"32","author":"C Stanciu-Herrera","year":"2008","unstructured":"Stanciu-Herrera C, Morgan C, Herrera L: Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines. Leuk Res. 2008, 32: 625-632. 10.1016\/j.leukres.2007.07.002.","journal-title":"Leuk Res"},{"key":"385_CR19","doi-asserted-by":"publisher","first-page":"15178","DOI":"10.1073\/pnas.0505539102","volume":"102","author":"N Yazawa","year":"2005","unstructured":"Yazawa N, Hamaguchi Y, Poe JC, Tedder TF: Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A. 2005, 102: 15178-15183. 10.1073\/pnas.0505539102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"385_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.1365-2443.2011.01552.x","volume":"16","author":"T Mizushima","year":"2011","unstructured":"Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K: Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 2011, 16: 1071-1080. 10.1111\/j.1365-2443.2011.01552.x.","journal-title":"Genes Cells"},{"key":"385_CR21","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jmb.2004.01.007","volume":"336","author":"A Okazaki","year":"2004","unstructured":"Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K: Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol. 2004, 336: 1239-1249. 10.1016\/j.jmb.2004.01.007.","journal-title":"J Mol Biol"},{"key":"385_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/leu.2013.5","volume":"27","author":"K Matlawska-Wasowska","year":"2013","unstructured":"Matlawska-Wasowska K, Ward E, Stevens S, Wang Y, Herbst R, Winter SS, Wilson BS: Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia. 2013, 27: 1263-1274. 10.1038\/leu.2013.5.","journal-title":"Leukemia"},{"key":"385_CR23","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3109\/10428194.2013.781169","volume":"54","author":"DJ Kern","year":"2013","unstructured":"Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ: GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma. 2013, 54: 2500-2505. 10.3109\/10428194.2013.781169.","journal-title":"Leuk Lymphoma"},{"key":"385_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.molimm.2012.01.001","volume":"50","author":"JR Gasdaska","year":"2012","unstructured":"Gasdaska JR, Sherwood S, Regan JT, Dickey LF: An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol. 2012, 50: 134-141. 10.1016\/j.molimm.2012.01.001.","journal-title":"Mol Immunol"},{"key":"385_CR25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/jcp.51.5.364","volume":"51","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D: Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998, 51: 364-369. 10.1136\/jcp.51.5.364.","journal-title":"J Clin Pathol"},{"key":"385_CR26","first-page":"5810","volume":"9","author":"CF Eisenbeis","year":"2003","unstructured":"Eisenbeis CF, Caligiuri MA, Byrd JC: Rituximab: converging mechanisms of action in non-Hodgkin\u2019s lymphoma?. Clin Cancer Res. 2003, 9: 5810-5812.","journal-title":"Clin Cancer Res"},{"key":"385_CR27","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003, 22: 7359-7368. 10.1038\/sj.onc.1206939.","journal-title":"Oncogene"},{"key":"385_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/jpet.110.168062","volume":"335","author":"R Herbst","year":"2010","unstructured":"Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall'Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ: B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010, 335: 213-222. 10.1124\/jpet.110.168062.","journal-title":"J Pharmacol Exp Ther"},{"key":"385_CR29","doi-asserted-by":"publisher","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","volume":"68","author":"HM Horton","year":"2008","unstructured":"Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA: Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008, 68: 8049-8057. 10.1158\/0008-5472.CAN-08-2268.","journal-title":"Cancer Res"},{"key":"385_CR30","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2008-10-182048","volume":"113","author":"J Zalevsky","year":"2009","unstructured":"Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE: The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood. 2009, 113: 3735-3743. 10.1182\/blood-2008-10-182048.","journal-title":"Blood"},{"key":"385_CR31","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.4049\/jimmunol.154.7.3096","volume":"154","author":"N Chaouchi","year":"1995","unstructured":"Chaouchi N, Vazquez A, Galanaud P, Leprince C: B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol. 1995, 154: 3096-3104.","journal-title":"J Immunol"},{"key":"385_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10495-006-6314-5","volume":"11","author":"I Daniels","year":"2006","unstructured":"Daniels I, Abulayha AM, Thomson BJ, Haynes AP: Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis. 2006, 11: 1013-1023. 10.1007\/s10495-006-6314-5.","journal-title":"Apoptosis"},{"key":"385_CR33","first-page":"5480","volume":"63","author":"HT Chan","year":"2003","unstructured":"Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS: CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003, 63: 5480-5489.","journal-title":"Cancer Res"},{"key":"385_CR34","first-page":"2143","volume":"119","author":"A Ivanov","year":"2009","unstructured":"Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS: Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009, 119: 2143-2159.","journal-title":"J Clin Invest"},{"key":"385_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrm2245","volume":"8","author":"DJ Klionsky","year":"2007","unstructured":"Klionsky DJ: Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 2007, 8: 931-937. 10.1038\/nrm2245.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"385_CR36","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood-2011-12-395541","volume":"119","author":"J Honeychurch","year":"2012","unstructured":"Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM: Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012, 119: 3523-3533. 10.1182\/blood-2011-12-395541.","journal-title":"Blood"},{"key":"385_CR37","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1182\/blood-2010-08-303354","volume":"117","author":"L Alinari","year":"2011","unstructured":"Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Pr\u00e6torius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA: Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011, 117: 4530-4541. 10.1182\/blood-2010-08-303354.","journal-title":"Blood"},{"key":"385_CR38","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1038\/sj.onc.1207741","volume":"23","author":"V Cerisano","year":"2004","unstructured":"Cerisano V, Aalto Y, Perdichizzi S, Bernard G, Manara MC, Benini S, Cenacchi G, Preda P, Lattanzi G, Nagy B, Knuutila S, Colombo MP, Bernard A, Picci P, Scotlandi K: Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing\u2019s sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene. 2004, 23: 5664-5674. 10.1038\/sj.onc.1207741.","journal-title":"Oncogene"},{"key":"385_CR39","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1182\/blood-2011-01-331702","volume":"118","author":"M Jak","year":"2011","unstructured":"Jak M, Van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P, Klein C, Van Lier RA, Van Oers MH, Eldering E: CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood. 2011, 118: 5178-5188. 10.1182\/blood-2011-01-331702.","journal-title":"Blood"},{"key":"385_CR40","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2010-07-296913","volume":"117","author":"W Alduaij","year":"2011","unstructured":"Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011, 117: 4519-4529. 10.1182\/blood-2010-07-296913.","journal-title":"Blood"},{"key":"385_CR41","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1053\/j.seminoncol.2006.01.024","volume":"33","author":"BD Cheson","year":"2006","unstructured":"Cheson BD: Monoclonal antibody therapy for B-cell malignancies. Semin Oncol. 2006, 33: S2-14.","journal-title":"Semin Oncol"},{"key":"385_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","volume":"2007","author":"C Bello","year":"2007","unstructured":"Bello C, Sotomayor EM: Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007, 2007: 233-242. 10.1182\/asheducation-2007.1.233.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"385_CR43","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","volume":"108","author":"C Ferrara","year":"2011","unstructured":"Ferrara C, Grau S, Jager C, Sondermann P, Brunker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Uma\u00f1a P, Benz J: Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011, 108: 12669-12674. 10.1073\/pnas.1108455108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"385_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4161\/mabs.19941","volume":"4","author":"S Chung","year":"2012","unstructured":"Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, Vanderlaan M, Song A: Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs. 2012, 4: 326-340. 10.4161\/mabs.19941.","journal-title":"MAbs"},{"key":"385_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2407-9-58","volume":"9","author":"S Iida","year":"2009","unstructured":"Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, Shitara K, Satoh M: Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009, 9: 58-10.1186\/1471-2407-9-58.","journal-title":"BMC Cancer"},{"key":"385_CR46","first-page":"7","volume":"3","author":"A Natsume","year":"2009","unstructured":"Natsume A, Niwa R, Satoh M: Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther. 2009, 3: 7-16.","journal-title":"Drug Des Devel Ther"},{"key":"385_CR47","doi-asserted-by":"publisher","first-page":"e42426","DOI":"10.1371\/journal.pone.0042426","volume":"7","author":"S Mohseni Nodehi","year":"2012","unstructured":"Mohseni Nodehi S, Repp R, Kellner C, Brautigam J, Staudinger M, Schub N, Peipp M, Gramatzki M, Humpe A: Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96. PLoS ONE. 2012, 7: e42426-10.1371\/journal.pone.0042426.","journal-title":"PLoS ONE"},{"key":"385_CR48","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","volume":"115","author":"SA Beers","year":"2010","unstructured":"Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS: Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010, 115: 5191-5201. 10.1182\/blood-2010-01-263533.","journal-title":"Blood"},{"key":"385_CR49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3324\/haematol.13690","volume":"94","author":"S Barbier","year":"2009","unstructured":"Barbier S, Chatre L, Bras M, Sancho P, Roue G, Virely C, Yuste VJ, Baudet S, Rubio M, Esquerda JE, Sarfati M, Merle-B\u00e9ral H, Susin SA: Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the F-actin cytoskeleton. Haematologica. 2009, 94: 507-517. 10.3324\/haematol.13690.","journal-title":"Haematologica"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-7-33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T03:41:59Z","timestamp":1689133319000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-7-33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,14]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-7-33","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,14]]},"assertion":[{"value":"10 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"33"}}